



Signalife

Clear Data. Trusted Results.

Signalife, Inc.
531 South Main St. ~ Suite 301
Greenville, SC 29601
T 864.233.2300
F 864.233.2100
www.signalife.com
info@signalife.com

PRESS RELEASE

Tuesday January 23, 2007 11:30 am ET

Signalife's 'Credit Card' Personal Event Monitor

GREENVILLE, S.C., Jan. 23 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News), the revolutionary heart monitoring company, announced today that it has completed design and manufacturing specifications for fabrication of its state-of-the-art "personal" event monitor. The device, which is essentially the size of a "credit card," utilizes a micro-engineered version of the Company's patented "patient module" found in the flagship "Fidelity 100" product currently being distributed. The difference between the two devices is that the "Fidelity 100" utilizes the clinical standard of 12-leads for hospital, surgical and other standard medical environments. The "personal event monitor" -- called the "Signalife Heart Card" ("SHC") -- is held over the center of a patient's chest to detect cardiac status. A patient can carry the SHC in his wallet and pull it out at any time in order to monitor the cardiac signal emanating from his chest, for transmission and review by monitoring centers or physicians.

The Company has been developing the SHC for some time, and the fabrication specifications are of critical importance in view of the size and configuration of the device. Extensive testing was completed by the company in order to validate the precise specifications, and enable regulatory and manufacturing work to now be completed. It is anticipated that the device will be ready for full scale distribution in the third quarter of this year.

Budimir S. Drakulic, the Company's CTO, stated: "To have met this milestone in a timely manner is very exciting for the Company. I must congratulate our R&D team for hard work, vigorous testing and analysis that has gone into these fabrication models. When people in our society are able to access the use of our patented award winning "patient module" in over-the-counter settings (i.e., without prescription), the opportunity for cardiac disease evaluation and subsequent opportunity of prevention is obviously maximized."

The SHC must still pass regulatory approval, and subsequent testing as well as other scientific and manufacturing regulatory hurdles. The Company is confident that these will be timely accomplished and is looking forward to movement toward the marketplace.

About Signalife, Inc.

Signalife, Inc. engages in the research, development, and marketing of signal-monitoring devices for detecting diseases. It primarily offers patient modules that are used as part of a heart monitor system to acquire, amplify, and process physiological signals associated with a patient's cardiovascular system. Signalife is based in Greenville, South Carolina. For more information visit <http://www.signalife.com>.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.

###